Posts Tagged


Oct 2020

NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial

Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
Oct 2020

Bio-IT World Conference w/ Mark Davies

Join Mark Davies for a talk on The Emergence of the AI Augmented Drug Discoverer and how integration of data is the foundation of which everything else is based, and describe our approach to using AI and human expertise to improve the drug development process.
Oct 2020

Elrig Drug Discovery Digital w/ Amparo Toboso-Navasa

We present an approach that we have developed using omics data to identify patient subgroups, illustrated with a case study from our patient stratification drug discovery programs.
Sep 2020

AI and ML in Healthcare Virtual Event w/ Jackie Hunter

Join BenevolentAI Board Director Jackie Hunter at Bayer’s LifeHub UK virtual event for a discussion of machine learning and AI in healthcare, alongside Lionel Tarassenko.